Retatrutide
WEIGHT MANAGEMENTQuick Specifications
| Vial Size | 24MG |
|---|---|
| BAC Water | 2.4ML |
| Amount Per Unit | 0.1MG PER UNIT |
| Recommended Dose | TITRATE UP FROM 2MG TO 12MG (20 TO 120 UNITS) |
| Frequency | 1X PER WEEK |
| Injection Type | SUBCUTANEOUS |
| Timing | Same Day Every Week / Starting Dose Is 2 MG |
Research Overview
GLP-3 class peptides are triple receptor agonists targeting GLP-1, GIP, and glucagon receptors simultaneously. Adding glucagon receptor activation to the dual GLP-1/GIP mechanism introduces a third lever: glucagon signaling increases energy expenditure and hepatic fat metabolism, which further amplifies the fat-reduction signal beyond what dual agonists achieve. The three receptor pathways work synergistically across the brain, liver, pancreas, and adipose tissue. Phase 2 clinical research on triple agonists showed mean body weight reduction of 24.2% at 48 weeks, with participants still losing weight at study end — indicating a plateau had not yet been reached. Phase 3 data has since reported up to 28.7% weight loss. The glucagon component also increases energy expenditure, which researchers propose may explain the energy and cognitive benefits often reported alongside weight reduction. Gastrointestinal tolerability is generally comparable to dual agonists. For research and educational purposes only. Independent purity testing warning (June 2026): 37 of 37 independently tested grey-market retatrutide samples received failing purity grades per Chainalysis reporting. Source only from vendors providing current, batch-specific HPLC certificates of analysis.
How It Works
GLP-1 Receptor Agonism — Appetite Suppression
Retatrutide activates GLP-1 receptors in the hypothalamus and brainstem, triggering satiety signaling that reduces caloric intake. This is the foundational mechanism shared with semaglutide and tirzepatide. GLP-1 receptor agonism also enhances glucose-dependent insulin secretion and slows gastric emptying, contributing to sustained fullness after meals.
GIP Co-Agonism — Metabolic Efficiency and GI Tolerability
Simultaneous GIP receptor activation enhances insulin secretion through a complementary intracellular pathway that converges on overlapping cellular machinery in the pancreas, brain, and adipose tissue. Critically, GIP co-agonism improves GI tolerability of the GLP-1 component — explaining why tirzepatide and Retatrutide produce less nausea than semaglutide at weight-loss-equivalent doses.
Glucagon Receptor Agonism — Energy Expenditure
The third and distinguishing mechanism: glucagon receptor activation increases resting metabolic rate and drives hepatic fat oxidation. While glucagon alone raises blood glucose, at the doses used in Retatrutide this effect is buffered by concurrent GLP-1 and GIP-mediated insulin sensitization. The net result is an energy expenditure increase that operates independently of appetite suppression — producing additive weight loss that neither mono nor dual agonism can match.
Commonly Studied With
These peptides are frequently researched alongside Retatrutide (GLP-1/GIP/Glucagon): 24mg due to complementary mechanisms:
Research references
The following PubMed resources are provided for educational reference. External links open in a new tab.
Retatrutide (GLP-1/GIP/Glucagon): 24mg information on this page is for research and educational purposes only. This content is not FDA-approved, does not constitute medical advice, and should not be used to guide personal health decisions. Consult a qualified healthcare professional before using any research compound.
Dose Calculator
Enter your target dose to calculate the volume to draw.
Recommended dose: TITRATE UP FROM 2MG TO 12MG (20 TO 120 UNITS)